调研基本信息 此次投资者关系活动类别为特定对象调研，于2025年9月17日在南京市鼓楼区集庆门大街270号公司49楼 会议室举行 。参与单位包括国泰海通证券的曾佳敏、国盛证券的夏陶等多家机构及相关人员。苏宁环 球接待人员有董事、副总裁、董事会秘书蒋立波，财务负责人刘得波，医美集团马国义以及证券部王 燕、赵亚洲、刘艳。 9月17日，苏宁环球接待了包括国泰海通证券、国盛证券、西南证券等在内的20家机构的调研。本次调 研就公司整体业务、地产业务、医美板块等方面展开交流，透露了苏宁环球地产、医美双主业发展的诸 多要点。 责任编辑：小浪快报 点击查看公告原文>> 苏宁环球业务发展要点双主业发展战略：苏宁环球以房地产开发与销售为主营业务，持续推进地产、医 美双主业发展战略。地产业务布局全国，深耕长三角区域；同时大力拓展医美领域，推进双主业协同发 展。地产业务经营情况：2025年房地产行业承压，但苏宁环球凭借三十年深耕，具备较强战略决策与规 划能力。公司持续深耕长三角，聚焦产品与服务，升级项目品质，构建全梯度产品体系，保障交付品 质。公司土地储备充足，总建面约155多万平方米，多位于长三角经济发达地区，土地成本低，抗风险 ...

证券代码：000718 证券简称：苏宁环球 苏宁环球股份有限公司 投资者关系活动记录表 5、公司地产业务的竞争优势 公司依托深厚的品牌积淀、优质的土地储备、卓越的管理 能力以及健康稳健的财务结构，构建起多维度、差异化的综合 竞争优势。2025 年半年度末，公司资产负债率仅为 29.74%， 扣除合同负债后的资产负债率低至 27.43%，财务安全边际较 高，良好健康的财务状况，为公司管理运营、业务发展及战略 投资提供坚实保障。公司践行"品质为先，以客户需求为中心" 的项目开发理念，持续优化产品结构，匠心打造精品项目。同 时公司着力优化地产业务营销体系，重点提升周边城市客群和 老带新客户等方式，在降低成本同时，有效提升增强营销效果， 在售项目如滨江雅园、荣锦瑞府等销售情况居于区域头部，持 续热销。 6、公司对投资者回报的规划 公司高度重视股东回报，持续多年进行现金分红，分红股 息率在全市场稳居前列，2022 年以来公司现金分红总额累计达 9.66 亿元，已实施完毕 8.75 亿元，未来公司将持续以良好的 经营业绩和分红回报广大股东。 | ☑ | 特定对象调研 □分析师会议 | | --- | --- | | 投资 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, indicating challenges in its operational performance while maintaining a healthy financial structure with a low debt ratio [2][5][12] Financial Performance - The company's operating revenue for the first half of 2025 was 933.64 million yuan, a decrease of 28.67% compared to the same period last year [2][5] - The net profit attributable to shareholders was 137.31 million yuan, down 45.51% year-on-year [2][5] - The net profit after deducting non-recurring gains and losses was also negative, with a cash flow from operating activities of -62.58 million yuan, a decline of 127.65% [2][5] Key Business Developments - The company focused on real estate and medical beauty as its dual main businesses, optimizing resource allocation and promoting multi-business synergy [6][10] - In the real estate sector, the company concentrated resources in the Yangtze River Delta region, enhancing product competitiveness through refined space planning and a comprehensive product system [6][10] - The company successfully launched key projects, such as the Nanjing Rongjin Ruifu, which received positive market feedback and achieved early high-quality delivery [6][7] Sales and Marketing Strategies - The company implemented targeted sales strategies, including limited-time discounts and promotional offers, to stimulate demand and accelerate sales recovery [7][8] - The sales performance of residential projects like Nanjing Rongjin Ruifu and Binjiang Yayuan was strong, with commercial project sales in cities like Nanjing and Wuxi seeing a 100.47% increase year-on-year [7][8] Medical Beauty Sector Growth - The medical beauty segment achieved significant growth, with total service visits reaching 78,273, an increase of 11.4%, and consumption visits at 39,862, up 18.1% [8][10] - The company’s medical beauty brand, Suya Medical Beauty, received multiple awards, enhancing its market reputation and customer satisfaction [8][10] Financial Health and Risk Management - The company maintained a low debt ratio of 29.74%, indicating a healthy financial structure and manageable debt risks [12] - The company emphasized risk management and compliance, implementing regular risk assessments and enhancing internal controls to ensure sustainable development [9][12]

Group 1: Medical Aesthetics Business Development - The company plans to increase investment in the medical aesthetics sector, aiming to enhance the market recognition and reputation of the Suya Medical Aesthetics brand. In 2025, new medical aesthetics institutions are planned to open in Jiangsu and Shanghai [2][3] - In 2024, the medical aesthetics segment achieved revenue of 179 million yuan and is currently profitable. The company will continue to focus on self-built facilities and expand in high-consumption areas like the Yangtze River Delta [5][6] Group 2: Shareholder Engagement and Stock Performance - In 2024, the actual controller and some executives completed a round of share buybacks, demonstrating confidence in the company's long-term investment value [3][4] - The company is committed to a "long-termism" approach, focusing on stable operations and long-term value creation, despite current market pressures affecting stock prices [4][6] Group 3: Strategic Business Direction - The company is dedicated to developing medical aesthetics and biopharmaceuticals, emphasizing a long-term strategy and resource optimization to enhance operational efficiency and profitability [3][5] - Future business expansion will include exploring new industries and opportunities, with a focus on maintaining a balanced approach to growth and avoiding reckless expansion [5][6] Group 4: Market Conditions and Company Response - The company's stock price has been under pressure due to macroeconomic factors, industry developments, and investor expectations. The company aims to improve product quality, brand building, and customer service to enhance overall competitiveness [6][7] - New medical aesthetics facilities are under construction, with plans for trial operations expected around mid-year [6][7]